{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:13:05Z","timestamp":1761513185262},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,9,8]],"date-time":"2012-09-08T00:00:00Z","timestamp":1347062400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s11864-012-0211-7","type":"journal-article","created":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T06:13:00Z","timestamp":1346998380000},"page":"527-534","source":"Crossref","is-referenced-by-count":10,"title":["Treatment Updates in Advanced Thymoma and Thymic Carcinoma"],"prefix":"10.1007","volume":"13","author":[{"given":"Matthew A.","family":"Gubens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,8]]},"reference":[{"key":"211_CR1","first-page":"161","volume":"170","author":"R Temes","year":"1999","unstructured":"Temes R, Chavez T, Mapel D, et al. Primary mediastinal malignancies: findings in 219 patients. West J Med. 1999;170:161\u20136.","journal-title":"West J Med"},{"key":"211_CR2","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.athoracsur.2008.12.095","volume":"87","author":"S Tomaszek","year":"2009","unstructured":"Tomaszek S, Wigle DA, Keshavjee S, Fischer S. Thymomas: review of current clinical practice. Ann Thorac Surg. 2009;87:1973\u201380.","journal-title":"Ann Thorac Surg"},{"key":"211_CR3","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ijc.11099","volume":"105","author":"EA Engels","year":"2003","unstructured":"Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer. 2003;105:546\u201351.","journal-title":"Int J Cancer"},{"key":"211_CR4","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.athoracsur.2003.07.042","volume":"77","author":"K Kondo","year":"2004","unstructured":"Kondo K, Yoshizawa K, Tsuyuguchi M, et al. WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg. 2004;77:1183\u20138.","journal-title":"Ann Thorac Surg"},{"key":"211_CR5","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1097\/JTO.0b013e3181f20c05","volume":"5","author":"A Masaoka","year":"2010","unstructured":"Masaoka A. Staging system of thymoma. J Thorac Oncol. 2010;5:S304\u201312.","journal-title":"J Thorac Oncol"},{"key":"211_CR6","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.6004\/jnccn.2010.0096","volume":"8","author":"DS Ettinger","year":"2010","unstructured":"Ettinger DS, Akerley W, Bepler G, et al. Thymic malignancies. J Natl Compr Canc Netw. 2010;8:1302\u201315.","journal-title":"J Natl Compr Canc Netw"},{"key":"211_CR7","doi-asserted-by":"crossref","first-page":"S348","DOI":"10.1097\/JTO.0b013e3181f20f27","volume":"5","author":"M Lucchi","year":"2010","unstructured":"Lucchi M, Mussi A. Surgical treatment of recurrent thymomas. J Thorac Oncol. 2010;5:S348\u201351.","journal-title":"J Thorac Oncol"},{"key":"211_CR8","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jtcvs.2008.09.033","volume":"137","author":"M Lucchi","year":"2009","unstructured":"Lucchi M, Davini F, Ricciardi R, et al. Management of pleural recurrence after curative resection of thymoma. J Thorac Cardiovasc Surg. 2009;137:1185\u20139.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"211_CR9","doi-asserted-by":"crossref","first-page":"S1749","DOI":"10.1097\/JTO.0b013e31821ea5f7","volume":"6","author":"N Girard","year":"2011","unstructured":"Girard N, Lal R, Wakelee H, Riely GJ, Loehrer PJ. Chemotherapy definitions and policies for thymic malignancies. J Thorac Oncol. 2011;6:S1749\u201355.","journal-title":"J Thorac Oncol"},{"key":"211_CR10","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","volume":"12","author":"PJ Loehrer Sr","year":"1994","unstructured":"Loehrer Sr PJ, Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol. 1994;12:1164\u20138.","journal-title":"J Clin Oncol"},{"key":"211_CR11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2003.12.010","volume":"44","author":"ES Kim","year":"2004","unstructured":"Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer. 2004;44:369\u201379.","journal-title":"Lung Cancer"},{"key":"211_CR12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","volume":"68","author":"A Fornasiero","year":"1991","unstructured":"Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer. 1991;68:30\u20133.","journal-title":"Cancer"},{"key":"211_CR13","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","volume":"29","author":"GL Lemma","year":"2011","unstructured":"Lemma GL, Lee JW, Aisner SC, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol. 2011;29:2060\u20135.","journal-title":"J Clin Oncol"},{"key":"211_CR14","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","volume":"14","author":"G Giaccone","year":"1996","unstructured":"Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1996;14:814\u201320.","journal-title":"J Clin Oncol"},{"key":"211_CR15","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","volume":"91","author":"PJ Loehrer Sr","year":"2001","unstructured":"Loehrer Sr PJ, Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer. 2001;91:2010\u20135.","journal-title":"Cancer"},{"key":"211_CR16","first-page":"7079","volume":"24","author":"PJ Loehrer","year":"2006","unstructured":"Loehrer PJ, Yiannoutsos CT, Dropcho S, et al. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. ASCO Annu Meet Proc. 2006;24:7079.","journal-title":"ASCO Annu Meet Proc"},{"key":"211_CR17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00003072-199901000-00006","volume":"24","author":"K Lin","year":"1999","unstructured":"Lin K, Nguyen BD, Ettinger DS, Chin BB. Somatostatin receptor scintigraphy and somatostatin therapy in the evaluation and treatment of malignant thymoma. Clin Nucl Med. 1999;24:24\u20138.","journal-title":"Clin Nucl Med"},{"key":"211_CR18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","volume":"22","author":"PJ Loehrer Sr","year":"2004","unstructured":"Loehrer Sr PJ, Wang W, Johnson DH, Aisner SC, Ettinger DS. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol. 2004;22:293\u20139.","journal-title":"J Clin Oncol"},{"key":"211_CR19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/COC.0b013e318209a8f8","volume":"35","author":"F Longo","year":"2012","unstructured":"Longo F, De Filippis L, Zivi A, et al. Efficacy and tolerability of long-acting octreotide in the treatment of thymic tumors: results of a pilot trial. Am J Clin Oncol. 2012;35:105\u20139.","journal-title":"Am J Clin Oncol"},{"key":"211_CR20","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1999.17.9.2737","volume":"17","author":"MS Highley","year":"1999","unstructured":"Highley MS, Underhill CR, Parnis FX, et al. Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol. 1999;17:2737\u201344.","journal-title":"J Clin Oncol"},{"key":"211_CR21","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","volume":"29","author":"G Giaccone","year":"2011","unstructured":"Giaccone G, Rajan A, Berman A, et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol. 2011;29:2052\u20139.","journal-title":"J Clin Oncol"},{"key":"211_CR22","first-page":"7103","volume":"30","author":"A Thomas","year":"2012","unstructured":"Thomas A, Rajan A, Khozin S, et al. A phase I\/II study of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in the first-line treatment of advanced or recurrent thymic malignancies. ASCO Annu Meet Proc. 2012;30:7103.","journal-title":"ASCO Annu Meet Proc"},{"key":"211_CR23","first-page":"7033","volume":"30","author":"A Rajan","year":"2012","unstructured":"Rajan A, Riely GJ, Carter CA, et al. Phase II study of cixitumumab (IMC-A12) in thymic malignancies. ASCO Annu Meet Proc. 2012;30:7033.","journal-title":"ASCO Annu Meet Proc"},{"key":"211_CR24","first-page":"e17513","volume":"30","author":"K Yoh","year":"2012","unstructured":"Yoh K, Goto K, Niho S, Umemura S, Ohmatsu H, Ohe Y. Efficacy and safety of amrubicin in patients with advanced or recurrent thymoma. ASCO Annu Meet Proc. 2012;30:e17513.","journal-title":"ASCO Annu Meet Proc"},{"key":"211_CR25","first-page":"S528","volume":"5","author":"H Wakelee","year":"2010","unstructured":"Wakelee H, Gubens MA, Burns M, et al. A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. J Thorac Oncol. 2010;5:S528.","journal-title":"J Thorac Oncol"},{"key":"211_CR26","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.6004\/jnccn.2010.0097","volume":"8","author":"RT Cheney","year":"2010","unstructured":"Cheney RT. The biologic spectrum of thymic epithelial neoplasms: current status and future prospects. J Natl Compr Canc Netw. 2010;8:1322\u20138.","journal-title":"J Natl Compr Canc Netw"},{"key":"211_CR27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1514","volume":"202","author":"CC Pan","year":"2004","unstructured":"Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol. 2004;202:375\u201381.","journal-title":"J Pathol"},{"key":"211_CR28","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","volume":"350","author":"P Strobel","year":"2004","unstructured":"Strobel P, Hartmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med. 2004;350:2625\u20136.","journal-title":"N Engl J Med"},{"key":"211_CR29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.lungcan.2008.03.035","volume":"62","author":"M Tsuchida","year":"2008","unstructured":"Tsuchida M, Umezu H, Hashimoto T, et al. Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer. 2008;62:321\u20135.","journal-title":"Lung Cancer"},{"key":"211_CR30","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","volume":"4","author":"G Giaccone","year":"2009","unstructured":"Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PC. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol. 2009;4:1270\u20133.","journal-title":"J Thorac Oncol"},{"key":"211_CR31","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/cncr.20811","volume":"103","author":"DN Ionescu","year":"2005","unstructured":"Ionescu DN, Sasatomi E, Cieply K, Nola M, Dacic S. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer. 2005;103:630\u20136.","journal-title":"Cancer"},{"key":"211_CR32","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2006.07.003","volume":"248","author":"M Meister","year":"2007","unstructured":"Meister M, Schirmacher P, Dienemann H, et al. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Lett. 2007;248:186\u201391.","journal-title":"Cancer Lett"},{"key":"211_CR33","first-page":"7068","volume":"23","author":"A Kurup","year":"2005","unstructured":"Kurup A, Burns M, Dropcho S, Pao W, Loehrer PJ. Phase II study of gefitinib treatment in advanced thymic malignancies. ASCO Annu Meet Proc. 2005;23:7068.","journal-title":"ASCO Annu Meet Proc"},{"key":"211_CR34","first-page":"19087","volume":"26","author":"PM Bedano","year":"2008","unstructured":"Bedano PM, Perkins S, Burns M, et al. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. ASCO Ann Meet Proc. 2008;26:19087.","journal-title":"ASCO Ann Meet Proc"},{"key":"211_CR35","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","volume":"12","author":"G Palmieri","year":"2007","unstructured":"Palmieri G, Marino M, Salvatore M, et al. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci. 2007;12:757\u201361.","journal-title":"Front Biosci"},{"key":"211_CR36","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","volume":"15","author":"N Girard","year":"2009","unstructured":"Girard N, Shen R, Guo T, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res. 2009;15:6790\u20139.","journal-title":"Clin Cancer Res"},{"key":"211_CR37","doi-asserted-by":"crossref","first-page":"S365","DOI":"10.1097\/JTO.0b013e3181f22d01","volume":"5","author":"F Detterbeck","year":"2010","unstructured":"Detterbeck F. International thymic malignancies interest group: a way forward. J Thorac Oncol. 2010;5:S365\u201370.","journal-title":"J Thorac Oncol"},{"key":"211_CR38","doi-asserted-by":"crossref","first-page":"S1691","DOI":"10.1097\/JTO.0b013e3182254ac1","volume":"6","author":"J Huang","year":"2011","unstructured":"Huang J, Detterbeck FC, Wang Z, Loehrer Sr PJ. Standard outcome measures for thymic malignancies. J Thorac Oncol. 2011;6:S1691\u20137.","journal-title":"J Thorac Oncol"},{"key":"211_CR39","doi-asserted-by":"crossref","first-page":"S1689","DOI":"10.1097\/JTO.0b013e31821e7afe","volume":"6","author":"FC Detterbeck","year":"2011","unstructured":"Detterbeck FC, Huang J. Overview. J Thorac Oncol. 2011;6:S1689\u201390.","journal-title":"J Thorac Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-012-0211-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-012-0211-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-012-0211-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:34:24Z","timestamp":1559417664000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-012-0211-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,8]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["211"],"URL":"https:\/\/doi.org\/10.1007\/s11864-012-0211-7","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,8]]}}}